Trinity Biotech Plc Stock Today
| TRIB Stock | USD 0.73 0.01 1.35% |
PerformanceOK
| Odds Of DistressAbove Average
|
Trinity Biotech is trading at 0.73 as of the 21st of July 2025, a 1.35 percent decrease since the beginning of the trading day. The stock's open price was 0.74. Trinity Biotech has over 57 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 22nd of April 2025 and ending today, the 21st of July 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 18th of August 1995 | Category Healthcare | Classification Health Care |
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the Americas, Africa, Asia, and Europe. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. The company has 18.63 M outstanding shares of which 804.76 K shares are at this time shorted by private and institutional investors with about 0.85 trading days to cover. More on Trinity Biotech plc
Moving against Trinity Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Trinity Stock Highlights
| CEO, President | John Gillard | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTrinity Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Trinity Biotech's financial leverage. It provides some insight into what part of Trinity Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trinity Biotech plc (TRIB) is traded on NASDAQ Exchange in USA. It is located in IDA Business Park, Bray, Ireland, A98 H5C8 and employs 401 people. Trinity Biotech is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.61 M. Trinity Biotech plc conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 18.63 M outstanding shares of which 804.76 K shares are at this time shorted by private and institutional investors with about 0.85 trading days to cover.
Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check Trinity Biotech Probability Of Bankruptcy
Ownership AllocationTrinity Biotech plc shows a total of 18.63 Million outstanding shares. Trinity Biotech plc has 12.01 % of its outstanding shares held by insiders and 4.62 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Trinity Ownership Details
Trinity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Investments Llc | 2025-03-31 | 15.1 K | |
| Integrys Wealth Advisors Llc | 2025-06-30 | 10 K | |
| Advisor Group Holdings, Inc. | 2025-03-31 | 4.5 K | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 2.2 K | |
| Rhumbline Advisers | 2025-03-31 | 1.3 K | |
| Jones Financial Companies Lllp | 2025-03-31 | 468 | |
| Atlantic Trust Group, Llc | 2025-03-31 | 222 | |
| Simplex Trading, Llc | 2025-03-31 | 215 | |
| Bank Of America Corp | 2025-03-31 | 40.0 | |
| Hunter Associates Inc. | 2025-03-31 | 375.1 K | |
| Whitefort Capital Management, Lp. | 2025-03-31 | 81.9 K |
Trinity Biotech Historical Income Statement
Trinity Stock Against Markets
Trinity Biotech Corporate Management
| Simon Dunne | Chief Officer | Profile | |
| Fernando Devia | Ex Sales | Profile | |
| Eibhlin Kelly | Chief Officer | Profile | |
| Susan OConnor | Interim Officer | Profile | |
| Aris Kekedjian | CEO Chairman | Profile | |
| Louise Tallon | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (1.80) | Revenue Per Share | Quarterly Revenue Growth 0.181 | Return On Assets |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.